Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donepezil

H M Bryson1, P Benfield

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Donepezil effectively treats mild to moderate Alzheimer's disease by inhibiting acetylcholinesterase, improving cognitive and global function. Common side effects include gastrointestinal issues and dizziness, with no reported liver toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Drugs·2017
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

SCF(beta-TRCP) and phosphorylation dependent ubiquitinationof I kappa B alpha catalyzed by Ubc3 and Ubc4.

Oncogene·2000
Same author

Fosphenytoin. Pharmacoeconomic implications of therapy.

PharmacoEconomics·1999
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Geriatrics

Background:

  • Alzheimer's disease is a progressive neurodegenerative disorder.
  • Acetylcholinesterase inhibitors are a key therapeutic class for Alzheimer's.
  • Donepezil is a selective and potent acetylcholinesterase inhibitor.

Purpose of the Study:

  • To evaluate the efficacy and safety of donepezil in patients with mild to moderate Alzheimer's disease.
  • To assess the impact of donepezil on cognitive function and global patient status.

Main Methods:

  • In vitro and in vivo studies to determine acetylcholinesterase inhibitory activity.
  • Animal models to assess memory function.
  • Randomized, placebo-controlled clinical trials in patients with mild to moderate Alzheimer's disease.

Related Experiment Videos

Main Results:

  • Donepezil demonstrated significant improvements in cognitive function (ADAS-cog) and global function after 14 and 30 weeks compared to placebo.
  • Long-term treatment (2 years) showed sustained cognitive benefits.
  • Most common adverse events were gastrointestinal disturbances and dizziness; no hepatotoxicity was observed.

Conclusions:

  • Donepezil is an effective treatment for improving cognitive and global function in mild to moderate Alzheimer's disease.
  • The drug is generally well-tolerated, with a manageable side effect profile.
  • Donepezil offers a valuable therapeutic option for managing Alzheimer's symptoms.